On this page
Hypokalaemic periodic paralysis
This condition involves sudden, temporary attacks of muscle weakness or paralysis, typically affecting the limbs and often triggered by factors like exercise or high-carbohydrate meals. It is a genetic condition that impacts muscle function.
Overview
Hypokalaemic periodic paralysis (HypoPP) is a rare genetic condition that causes episodes of muscle weakness or paralysis. These episodes can range from mild weakness in specific muscles to complete paralysis of the limbs and body, temporarily preventing movement. The term 'hypokalaemic' refers to the low levels of potassium in the blood that typically occur during an attack [PMID:33671239]. The 'periodic' nature indicates that these attacks happen intermittently, rather than being constant. While the muscle weakness is usually temporary and reversible, severe episodes can sometimes be life-threatening if they affect breathing muscles.
Symptoms & clinical features
The main symptom of HypoPP is sudden, temporary muscle weakness or paralysis. These attacks can last from a few hours to several days. They often begin in the early morning or after rest, and typically affect the muscles of the arms, legs, and sometimes the trunk [PMID:20301726]. Muscle pain can also occur during or after an attack. Though rare, some individuals may experience cardiac arrhythmias (irregular heartbeats) during an attack, which can be a serious complication. Over time, some people with HypoPP may develop persistent, mild muscle weakness even between attacks.
Video: Genetics 101
Affected organs
HypoPP primarily affects the skeletal muscles, which are the muscles responsible for voluntary movement of the body and limbs. During an attack, the ability of these muscles to contract properly is impaired, leading to weakness or paralysis. Although less common, the heart muscle (cardiac muscle) can also be affected in some individuals, potentially leading to rhythm disturbances. The brain and other internal organs are typically not directly affected by the condition itself.
Risks & severity
The severity and frequency of HypoPP attacks can vary widely among affected individuals, even within the same family. Some people may experience only a few mild episodes throughout their lives, while others may have frequent, severe attacks. Triggers for attacks commonly include strenuous exercise followed by rest, high-carbohydrate or high-sodium meals, alcohol consumption, stress, and exposure to cold [PMID:20301726]. Attacks usually begin in childhood or adolescence, often before the age of 20, but can start later. While most attacks are reversible, there is a small risk of severe complications, such as respiratory failure if the breathing muscles are significantly affected. In some cases, prolonged muscle weakness can develop over many years.
Genetic causes
HypoPP is caused by pathogenic variants in specific genes that play a crucial role in muscle function. The most commonly implicated genes are CACNA1S and SCN4A. These genes provide instructions for making protein channels that control the flow of ions, specifically calcium and sodium, into and out of muscle cells. These ion channels are essential for muscle contraction and relaxation [PMID:33671239]. When there is a pathogenic variant in CACNA1S or SCN4A, these ion channels do not function correctly. This faulty ion flow disrupts the electrical signalling in muscle cells, making them unable to contract effectively during episodes, leading to the characteristic muscle weakness.
- CACNA1S calcium voltage-gated channel subunit alpha1 S
- SCN4A sodium voltage-gated channel alpha subunit 4
Inheritance pattern
Hypokalaemic periodic paralysis is inherited in an autosomal dominant pattern. This means that a person only needs to inherit one copy of an altered gene (either CACNA1S or SCN4A) from one parent to develop the condition. If a parent has HypoPP, there is a 50% chance with each pregnancy that their child will also inherit the pathogenic variant and be affected. The condition affects males and females equally, although males often experience more frequent and severe attacks. Some cases can also arise from a new, spontaneous pathogenic variant in a person with no family history of the condition.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of HypoPP typically involves a review of an individual's symptoms and family medical history. Blood tests during an attack usually show low potassium levels. Electromyography (EMG), which measures muscle electrical activity, may also be used to assess muscle function. A definitive diagnosis is confirmed through genetic testing, which can identify pathogenic variants in the CACNA1S or SCN4A genes. In the UK, genetic testing for inherited muscle disorders, including periodic paralyses, is available through the NHS Genomic Medicine Service. A referral to a clinical genetics service or a neuromuscular specialist is typically made for such testing (relevant NHS R-codes include R148 and R149 for inherited neuromuscular disorders).
Management & lifestyle
Management of HypoPP focuses on preventing attacks and treating symptoms when they occur. Lifestyle adjustments are often recommended, including avoiding known triggers such as strenuous exercise followed by rest, large carbohydrate-rich meals, and excessive alcohol. A diet low in sodium and carbohydrates, and rich in potassium, may be advised. Medications, such as acetazolamide or dichlorphenamide, may be prescribed to help prevent attacks or reduce their severity by influencing kidney function and potassium levels. During an acute attack, potassium supplements may be given under medical supervision to help restore normal muscle function. All management decisions should be made in consultation with a specialist physician [PMID:20301726].
UK care pathway
In the UK, individuals suspected of having Hypokalaemic periodic paralysis would typically be referred by their GP to a neurologist or a clinical genetics service. These specialists can evaluate symptoms, arrange for appropriate diagnostic tests, and provide genetic counselling. Genetic testing is provided through the NHS Genomic Medicine Service. Genetic counsellors can offer support and information about the condition, its inheritance pattern, and implications for family members. They also help patients navigate care pathways and discuss available management strategies.
Frequently asked questions
What is the main difference between hypokalaemic and hyperkalaemic periodic paralysis?
The key difference lies in blood potassium levels during an attack. Hypokalaemic periodic paralysis involves abnormally low potassium, while hyperkalaemic periodic paralysis involves abnormally high potassium. These differences guide diagnosis and treatment strategies.
Are there specific foods I should avoid if I have Hypokalaemic periodic paralysis?
Individuals with HypoPP are often advised to avoid meals high in carbohydrates and sodium, as these can trigger attacks. It's also generally recommended to limit alcohol. A balanced diet rich in potassium may be beneficial, but specific dietary advice should come from your doctor or a dietitian.
Can Hypokalaemic periodic paralysis be cured?
There is currently no cure for Hypokalaemic periodic paralysis. However, the condition can be managed effectively with lifestyle adjustments and medication to reduce the frequency and severity of attacks. The muscle weakness during attacks is usually temporary and reversible.
If I have Hypokalaemic periodic paralysis, will my children inherit it?
Hypokalaemic periodic paralysis is inherited in an autosomal dominant pattern. This means if you have the condition, each of your children has a 50% chance of inheriting the pathogenic variant and potentially developing the condition. Genetic counselling can provide more detailed information specific to your family.
How common is Hypokalaemic periodic paralysis?
Hypokalaemic periodic paralysis is a rare condition, affecting approximately 1 in 100,000 people. Due to its rarity, diagnosis can sometimes take time, but increased awareness among healthcare professionals is improving this.
References
- Ahlawat SK, Sachdev A. Hypokalaemic paralysis. Postgraduate medical journal. 1999. PMID: 10715756
- Stapleton LJ. Hypokalaemia periodic paralysis. Scottish medical journal. 2018. PMID: 28841083
- Benatar M. Neurological potassium channelopathies. QJM : monthly journal of the Association of Physicians. 2000. PMID: 11110585
- Familial hypokalaemic periodic paralysis. Lancet (London, England). 1981. PMID: 6112494
- Lin SH, Lin YF, Halperin ML. Hypokalaemia and paralysis. QJM : monthly journal of the Association of Physicians. 2001. PMID: 11259688
- Jitpimolmard N, Matthews E, Fialho D. Treatment Updates for Neuromuscular Channelopathies. Current treatment options in neurology. 2020. PMID: 32848354
- Schipperheyn JJ, Buruma OJ, Voogd PJ. Hypokalaemic periodic paralysis and cardiomyopathy. Acta neurologica Scandinavica. 1978. PMID: 742352
- Luo S, Sampedro Castañeda M, Matthews E. Hypokalaemic periodic paralysis and myotonia in a patient with homozygous mutation p.R1451L in Na(V)1.4. Scientific reports. 2018. PMID: 29946067